Background. Tuberculosis is the leading infectious cause of death. Steep reductions in tuberculosis-related mortality are required to realize the World Health Organization's "End Tuberculosis Strategy. " However, accurate mortality estimates are lacking in many countries, particularly following discharge from care. This study aimed to establish the mortality rate among patients with pulmonary tuberculosis in Vietnam and to quantify the excess mortality in this population.
With 10.4 million new cases and 1.3 million deaths annually, tuberculosis (TB) ranks as the leading global infectious cause of death [1] . The vast majority of these deaths occur in resourcelimited settings, where delays in diagnosis and treatment of TB often contribute to poor outcomes [2] [3] [4] . Recognizing the devastating individual and community impacts of TB mortality and the potential for interventions to mitigate those impacts, the 2015 World Health Organization (WHO) "End Tuberculosis Strategy" includes a commitment to reduce TB mortality by 95% by 2035 [5] . An important barrier to realizing this vision is the incomplete reporting of deaths in settings where TB is most prevalent [6] . Retrospective cohort studies have revealed that patients treated for TB have a substantially-elevated ongoing risk of death compared to the general population, even following apparently-successful treatment [7] [8] [9] [10] . However, reliance upon routinely-available data sources may substantially underestimate the mortality rate during and after treatment for the disease. Therefore, appropriately-controlled prospective studies are required to assess the post-treatment mortality rate among patients with TB in this high-risk population.
This study aimed to establish the mortality rate and causes of death among patients with pulmonary TB, during and after treatment in a high-prevalence setting. It also aimed to quantify the excess mortality in this population. In order to address these aims, we conducted a prospective cohort study of patients in a nationally-representative sample of patients treated for tuberculosis in Vietnam, together with a population of controls recruited from their households.
incidence of tuberculosis of 133 per 100 000 [1, 11] . Among patients with newly-diagnosed TB, human immunodeficiency virus (HIV) prevalence is 3.0% and multidrug-resistant (MDR)-TB prevalence is 4.1% [12] . Treatment success is reported for 91% of new and retreatment cases [1] . The standardized regimen given for newly-diagnosed TB during the study period was 8 months of multi-drug therapy (2 months of isoniazid, rifampicin, streptomycin, and ethambutol, followed by 6 months of isoniazid and ethambutol), in accordance with WHO and National Tuberculosis Program policy at the time of recruitment [13] . The National Tuberculosis Program transitioned to a 6-month regimen containing rifampicin throughout in 2015. Adherence was monitored by assigned family members, with clinic visits at least once a month. Within 8 of Vietnam's 63 provinces, including its 2 largest cities, we randomly selected 70 of 112 districts, with a probability of selection in proportion to their population. The combined population of the selected districts was 15.8 million people, comprising 18% of the entire Vietnamese population [14] . The cluster-randomized study aimed to determine the effectiveness of active case-finding among household contacts of TB patients, compared to routine, passive case detection [15] .
Participant Eligibility
Patients with sputum smear-positive pulmonary TB were eligible to enroll if they shared a house with at least 1 other person and were aged 15 years or over. In addition, persons aged 15 years and over living in the same household as these patients during the 2 months preceding the diagnosis of the index patient were eligible for recruitment as controls, unless they were already taking treatment for tuberculosis.
Study Procedures

Patient Recruitment and Treatment
Patients presenting consecutively to participating District Tuberculosis Clinics, and their household contacts (controls), were prospectively enrolled by health care workers. Patients provided demographic information and details of their symptoms and comorbidities. Microbiological test results were obtained from clinic records. Standardized antituberculous treatment was provided free of charge by the National Tuberculosis Program, according to national guidelines. Each patient' s reatment response was assessed on the basis of their sputum-smear status and clinical response, according to standard definitions (Supplementary Table S1 ). Patients whose sputum-smear status failed to convert after 5 months were given WHO retreatment regimens [13] . Second-line treatment for MDR-TB became available in participating provinces over the course of the study. Treatment outcomes were recorded in clinic registries, according to standard WHO definitions [16] .
Control Population
In the main Active Casefinding for Tuberculosis Study 2 (ACT2) Trial [15] , districts were randomly assigned to either receive an active screening intervention or usual care. Household members who were contacts in the intervention districts were offered a chest radiograph and clinical assessment at the time of enrollment, then again after 6, 12, and 24 months. In the standard-care districts, household members who were contacts were enrolled and asked to return after 24 months. Contacts in this group were not screened unless they developed symptoms and self-presented for assessment. Prophylactic treatment was not used routinely to treat household contacts in either group.
Participant Follow-up
After at least 24 months, TB patients and controls were followed up independently of the contact screening intervention. Follow-up interviews were conducted by research staff by telephone or, if a current phone number was unavailable, by household visit. For participants no longer living at the stated address, another adult household member was asked to provide further information. If participants had died during follow-up, their date of death was provided by other household members.
Patients who had completed treatment for TB were asked whether they had received a diagnosis of TB following discharge or loss to follow-up. For patients with a relapse diagnosed at a district clinic, information about their microbiological status and re-treatment regimen were gathered from clinic registers. For those who had died, family members were interviewed to establish whether patients had been retreated for TB prior to their death.
Relapse Among Patients
Independently of the process of participant follow-up, relapse status was determined by identifying participating patients in TB notification registries using probabilistic data linkage. The presence of incident TB among the control population was also established in this way. Notified TB was defined as an episode of TB treatment reported in the clinic registry. Notified relapse was notified TB occurring at least six months after the first diagnosis. Self-reported relapse was defined as a second episode of TB reported by patients during the follow-up interview, among those successfully completing treatment. Probabilistic data linkage was performed based upon name, age, gender, and district (see Supplementary Methods).
Verbal autopsies were performed among the household contacts of a random sample of patients who died, using the standardized 2012 WHO Verbal Autopsy tool [17] (see Supplementary Methods).
Study Outcomes
The primary outcome of this study was the all-cause mortality rate during the follow-up period. Secondary outcomes included the proportion of patients with notified relapses or self-reported relapses, the causes of death according to the tenth revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) classifications (based upon verbal autopsies), and the likelihood of TB as the primary cause of death. The standardized mortality ratio (SMR) was calculated by comparing the mortality rates between patients with TB and control participants, matching for age and gender.
Statistical Analysis
The primary and secondary outcomes were calculated using descriptive statistics. Univariate proportional hazards modeling was used to estimate the effect of various demographic and clinical variables on survival. A fully-adjusted multivariate proportional-hazards model using a robust sandwich estimator was fitted to assess the joint effects of factors from the univariate analyses, adjusting for an a priori set of confounding variables, as well as adjusting for the interaction between age and gender and accounting for clustering at the district level.
The SMR was calculated by determining the ratio of observed to expected mortality, using household controls aged 15 years and over as the referent population for age-and sex-stratified expected mortality.
As a supplementary analysis, we used multiple imputation to impute an overall mortality that included patients lost to follow-up, with age, gender, and rural or urban status as covariates in the model (Proc MI; SAS, Cary, NC).
Ethical Issues
Patients provided written informed consent to participate in the study during their initial treatment. The household members of deceased patients provided verbal informed consent prior to completing the verbal autopsy questionnaire. Ethical approval was obtained from the Human Research Ethics Committee at the University of Sydney and the Scientific Committee of the National Lung Hospital in Hanoi, Vietnam. Figure 1 shows participant recruitment and the outcomes of follow-up. Patients were followed for a total of 27 922 person-years. The median follow-up period for patients was 2.9 years (IQR 2.4-3.4 years). The characteristics of patients participating in the study are shown in Table 1 . Characteristics of control subjects are shown in Supplementary Table S2 [15] . Patient participation rates in each province, as a proportion of registered patients, are shown in Supplementary Table S3 .
RESULTS
Between
Overall, 9825 patients (89.6%) achieved a cure or completed treatment, with 342 deaths (3.1%) occurring during treatment. Smear conversion was achieved in 88.7%, while culture was not routinely performed to monitor treatment responses. Outcomes during initial treatment are shown in Supplementary Table S4 . A total of 9839 enrolled patients (89.7%) were successfully followed up by research staff at the end of the follow-up period (Supplementary Table S5 ). Of those followed up, 7464 (75.9%) stated that they completed at least 6 months of treatment.
Notified Relapse
Of the 9825 patients with documented treatment success (either cure or treatment completion) during their initial episode, 498 (5.1%) had notified relapses during the follow-up period. The mortality among patients with notified relapses is shown in Supplementary Figure S1 . The characteristics of patients with notified relapses are shown in Table 2 . Self-reported relapses were identified among 638 patients (6.1%) who successfully completed treatment, of which 498 had both notified and self-reported relapses.
In the multivariate model, a notified relapse was associated with HIV positivity (adjusted hazard ratio [aHR] 1.7, 95% confidence interval [CI] 1.1-2.4), prior history of TB treatment (aHR 2.3, 95% CI 2.0-2.7), self-reported history of MDR-TB (aHR 8.4, 95% CI 7.4 -9.6), and residence in an urban, rather than a rural, area (aHR 1.4, 95% CI 1.2-1.6). Age and gender were not independently associated with risk of relapse. Relapse rates varied considerably between provinces (Supplementary Table S6 ).
All-cause Mortality
Among all 10 964 enrolled patients, 979 patients (8.9%) died during the total follow-up period, including 342 deaths during treatment (3.1%) and 637 deaths (5.8%) following discharge from treatment (Table 4 ). The patient mortality rate was 4464 per 100 000 patients per year. The estimated overall mortality after imputation of missing outcomes was 1051 (9.59%), comprising an imputed mortality rate of 4793 per 100 000 patients per year. The mortality rate varied substantially between provinces (Supplementary Table S7 ). The proportion of deaths reported by other household members as caused by TB is shown in Supplementary Table S8 , and the correlation between the cause of death as identified through family member reports and verbal autopsies is shown in Supplementary Table S9 .
The characteristics of patients who died during follow-up are shown in Table 3 . All-cause mortality was associated with HIV positivity (aHR 5.1, 95% CI 4.2-6.3), a history of TB prior to the current episode (aHR 1.5, 1.4-1.6), living in an urban setting (aHR 1.1, 95% CI 1.0-1.3), and the time to smear conversion (aHR 1.1, 95% CI 1.0-1.1, for each additional month to smear conversion). The population attributable risk of death owing to these risk factors is shown in Supplementary Table S10.
Cause of Death According to Verbal Autopsies
Verbal autopsies were performed for 329 randomly-selected deceased TB patients, comprising 33.6% of all reported deaths. The likely causes of death, according to the ICD-10 classification system, are shown in Table 4 . The proportion of deaths attributable to TB is shown in Table 5 , grouped according to the timing of death in relation to treatment.
Incidence of Tuberculosis and All-cause Mortality Among Control Subjects
Control subjects were followed for a median period of 2.7 years (IQR 2.3-3.1 years) after enrollment. During follow-up, outcomes could be ascertained for 23 585 control subjects (91.7%). Among all 25 707 control subjects, 290 cases (1.2%) of notified TB were identified. Overall, 348 control subjects (1.4%) died prior to the end of follow-up (Supplementary Table S11 ). The all-cause mortality rate among control subjects was 738 per 100 000 contacts per year. The cause of death was assessed by verbal autopsy for 206 control subjects (Supplementary  Table S12 ).
Standardized Mortality Ratio
The overall SMR for patients with TB, relative to all control participants, after adjusting for age and gender, was 4.0 (95% CI 3.7-4.2) for the study population as a whole. When the control (reference) population was limited to household members in the control arm of the ACT2 Trial (ie, where serial screening was not performed), the SMR was 3.3 (95% CI 3.1-3.5).
DISCUSSION
In this prospective cohort study, in which we followed 10 964 patients with bacteriologically-confirmed TB for a median of 2.9 years after they commenced TB treatment, the risk of death was 4-fold higher than expected based on an age-and gender-matched reference population. Two-thirds of deaths occurred after patients were discharged from the TB program. However, both during and after treatment a majority of deceased patients had symptoms consistent with TB prior to their death. Importantly, the standard regimen used at the time was a likely contributor to the high recurrence rate. The National Tuberculosis Program provided 2 months of a rifampicin-based regimen, followed by 6 months of ethambutol and isoniazid. This regimen is recognized to have a high rate of relapse [13, 18] and is no longer used in Vietnam. This study provides important insights into the risk of death among patients treated for TB in resource-limited settings, and has important implications for the efforts to track progress against the targets of the End Tuberculosis Strategy [19] . TB was the most common cause of death within the first 3 years after diagnosis, comprising almost half of all deaths according to the verbal autopsies. Although the proportion of deaths reported to the National Tuberculosis Program during treatment was comparable to other settings [20, 21] , all-cause mortality was substantially higher when patients lost to follow-up and failing treatment were also included. This finding highlights the limitations inherent in the currently-accepted method of reporting deaths in resource-limited settings such as Vietnam. Patients lost to follow-up or discharged are not included in the reported TB mortality estimates. We have identified substantial under-reporting of TB-related mortality in a setting where the death registries are not routinely compiled.
Importantly, over 60% of deaths occurred during the period after documented treatment completion. This demonstrates that patients with TB remain a high-risk population even after having received standardized therapy. This finding aligns with long-term retrospective cohort studies, which have shown patients with TB experience an ongoing excess risk of death beyond the treatment period [7] [8] [9] 22] . The SMRs in these studies ranged from 3.6 to 5.2, which is consistent with the SMR of 4.0 we found among patients in Vietnam. Although the SMRs were similar between studies, the mortality rate in our study was substantially highier and deaths due to TB were more commen. This project supports those findings with the observation, based on verbal autopsies with household controls of a random sample of deceased patients, that the majority of these post-treatment deaths were due to possible or probable relapses of TB. Independent of the mortality findings, recurrence of TB was common in this cohort. We found that 5.1% of patients were notified as having a relapse of TB and that 6.1% of patients self-reported a relapse. These high rates of recurrence point towards inadequacies in the initial treatment regimen, due to inadequate adherence or an ineffective empirical regimen, leading to insufficient bacterial killing and subsequent recrudescence of the infection. Recognized causes of relapse include sub-optimal adherence during the continuation phase of treatment, undetected primary or acquired drug resistance, and severe disease [23] . This population also remains at a high risk of re-infection, owing to continuing exposure to high-transmission environments. Furthermore, susceptibility to exogenous re-infection may be further exacerbated by immunosuppression induced by the acute infection, as has been shown in recent studies of other respiratory pathogens [24] .
Another important finding was the high proportion of deaths due to non-communicable diseases, such as stroke and cancer. Given the high proportion of patients who smoked and the older age of the cohort, enrollment in TB treatment provides an ideal opportunity to offer primary prevention for cardiovascular 5-1.8)  1.5 (1.4-1.6) Age, per additional extra decade The hazard ratio was adjusted for age, gender, hemoptysis, HIV status, prior TB, self-reported drug-resistant TB, interaction between age and gender, and clustering at the district level.
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; TB, tuberculosis. a 9879 enrolled patients (90.1%) were able to be re-traced. All 10 964 enrolled patients were included in the denominator of the mortality estimate. diseases and cancer. In particular, smoking cessation advice and interventions to measure and treat hypertension and diabetes among TB patients may also be beneficial. These findings emphasize the importance of primary care for patients with TB, and the use of the acute episode as an opportunity to engage and prevent chronic disease.
This study has a number of strengths. Firstly, it includes a representative sample of patients with smear-positive pulmonary TB from 70 districts across the country. The follow-up rate was also high, with outcomes ascertained for 90% of patients after a median of 3 years following treatment initiation. Secondly, we obtained detailed information about the circumstances of patients' deaths by performing verbal autopsies with household contacts of a random sample of patients. This included information about the documented cause of death, as well as historical information from close relatives. This approach allowed us to establish the common causes of death, which provided important information that is relevant to strategies to reduce mortality in the future.
The study also had several limitations. While verbal autopsies can establish a likely cause of death, their sensitivity and specificity is limited compared to prospective cardiopulmonary autopsies [17, 25] . Nevertheless, this approach overcomes the limitations inherent in existing civil registration systems [26] and provides a standardized approach that draws upon all available sources to determine the most likely cause of death. Secondly, despite achieving a high follow-up rate, we are likely to have underestimated the true mortality. We addressed this limitation by using multiple imputation, incorporating all available information about patients to estimate the true mortality rate. Nevertheless, ascertainment bias remains a possibility. In addition, we were unable to distinguish true relapses from reinfection with a subsequent exogenous mycobacterial strain, as cultured isolates collected from the cohort were not available.
This study has important public health implications for Vietnam and internationally. Crucially, efforts to strengthen the diagnosis and treatment of TB will be critical to reducing the disease's recurrence and its concomitant mortality. Our findings demonstrate the importance of scaling up rapid molecular testing to detect multidrug-resistant disease, adherence to current WHO treatment guidelines, routine HIV testing, and optimization of patient adherence support. Research to better characterize local attitudes towards treatment adherence will be an essential step in optimizing treatment outcomes in high-burden settings. Secondly, relying solely upon routine programmatic reporting of treatment outcomes is likely to underestimate the true rate of mortality due to TB. In this study, just one-third of TB deaths were reported to the National Tuberculosis Program, with the remainder occurring after discharge from treatment. Consequently, new strategies to monitor death among a representative sample of patients will be important to track progress against agreed international targets to reduce TB mortality [19] . Finally, our study indicates the importance of non-infectious diseases in this population. Therefore, attention to the chronic non-communicable diseases, including cardiovascular disease, smoking-related lung disease, and cancer, is also an important priority.
CONCLUSION
Tuberculosis remains the leading preventable cause of death in many resource-limited settings, including Vietnam. We have found that current programmatic data substantially underestimate the burden of TB among affected populations. All-cause mortality is substantially higher among patients with TB compared to matched controls. The success of many high-income countries in reducing the mortality due to TB indicates that progress is possible. However, this will require new, evidence-based interventions that address the factors underlying treatment failure, as well as address the growing burden of non-communicable diseases. Such strategies are urgently required if the ambition of ending TB is to be realized.
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